Asset Planning Inc Purchases New Holdings in Edwards Lifesciences Co. (NYSE:EW)

Asset Planning Inc purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,922 shares of the medical research company's stock, valued at approximately $1,993,000. Edwards Lifesciences accounts for approximately 1.5% of Asset Planning Inc's portfolio, making the stock its 13th biggest holding.

Several other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Edwards Lifesciences during the 4th quarter worth $30,000. Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences during the third quarter valued at $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after purchasing an additional 308 shares during the period. Finally, JFS Wealth Advisors LLC raised its stake in shares of Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after purchasing an additional 166 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.7 %

EW stock traded down $0.52 during midday trading on Tuesday, reaching $75.67. The company had a trading volume of 4,937,936 shares, compared to its average volume of 4,574,817. The company has a 50 day moving average of $72.78 and a two-hundred day moving average of $69.68. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a market capitalization of $44.63 billion, a P/E ratio of 10.92, a PEG ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of several research analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Truist Financial reaffirmed a "hold" rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Daiwa America downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 30th. Finally, Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus target price of $79.95.

Insider Transactions at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.